Charles H Lawrie

List of Publications by Citations

94 papers	4,894 citations	32 h-index	69 g-index
99 ext. papers	5,506 ext. citations	6.3 avg, IF	5.49 L-index

#	Paper	IF	Citations
94	Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. *British Journal of Haematology*, **2008**, 141, 672-5	4.5	1389
93	Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. *Nature Genetics*, **2014**, 46, 176-181	36.3	475
92	MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. *International Journal of Cancer*, **2007**, 121, 1156-61	7.5	328
91	CircRNAs and cancer: Biomarkers and master regulators. *Seminars in Cancer Biology*, **2019**, 58, 90-99	12.7	177
90	New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	162
89	Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 1248-60	5.6	132
88	Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. *British Journal of Haematology*, **2007**, 139, 578-89	4.5	130
87	MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. *Blood*, **2010**, 116, 1105-13	2.2	117
86	MicroRNA profile of Marek‡s disease virus-transformed T-cell line MSB-1: predominance of virus-encoded microRNAs. *Journal of Virology*, **2008**, 82, 4007-15	6.6	115
85	MicroRNAs and haematology: small molecules, big function. *British Journal of Haematology*, **2007**, 137, 503-12	4.5	105
84	Marek‡s disease virus type 2 (MDV-2)-encoded microRNAs show no sequence conservation with those encoded by MDV-1. *Journal of Virology*, **2007**, 81, 7164-70	6.6	87
83	SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression. *Cancer Research*, **2016**, 76, 6735-6746	10.1	79
82	miRNA expression profiling of mycosis fungoides. *Molecular Oncology*, **2011**, 5, 273-80	7.9	79
81	MicroRNA expression in lymphocyte development and malignancy. *Leukemia*, **2008**, 22, 1440-6	10.7	76
80	MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. *Biology Direct*, **2011**, 6, 23	7.2	74
79	The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. *Journal of Cellular and Molecular Medicine*, **2015**, 19, 2307-23	5.6	64
78	Ixodes ticks: serum species sensitivity of anticomplement activity. *Experimental Parasitology*, **1999**, 93, 207-14	2.1	61

77	MicroRNAs and lymphomagenesis: a functional review. *British Journal of Haematology*, **2013**, 160, 571-81	4.5	58
76	Differential expression of microRNAs in Marek's disease virus-transformed T-lymphoma cell lines. *Journal of General Virology*, **2009**, 90, 1551-1559	4.9	54
75	The circulating transcriptome as a source of cancer liquid biopsy biomarkers. *Seminars in Cancer Biology*, **2019**, 58, 100-108	12.7	53
74	Oncogenic Roles and Inhibitors of DNMT1, DNMT3A, and DNMT3B in Acute Myeloid Leukaemia. *Biomarker Insights*, **2019**, 14, 1177271919846454	3.5	50
73	MicroRNA expression in lymphoid malignancies: new hope for diagnosis and therapy?. *Journal of Cellular and Molecular Medicine*, **2008**, 12, 1432-44	5.6	48
72	MicroRNAs in hematological malignancies. *Blood Reviews*, **2013**, 27, 143-54	11.1	45
71	Susceptibility of mosquito and tick cell lines to infection with various flaviviruses. *Medical and Veterinary Entomology*, **2004**, 18, 268-74	2.4	43
70	Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma. *Blood Cancer Journal*, **2013**, 3, e152	7	42
69	MicroRNA expression in lymphoma. *Expert Opinion on Biological Therapy*, **2007**, 7, 1363-74	5.4	41
68	Cancer-associated carbohydrate identification in Hodgkin's lymphoma by carbohydrate array profiling. *International Journal of Cancer*, **2006**, 118, 3161-6	7.5	41
67	Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. *Nature Communications*, **2015**, 6, 8428	17.4	39
66	Targeted next-generation sequencing and non-coding RNA expression analysis of clear cell papillary renal cell carcinoma suggests distinct pathological mechanisms from other renal tumour subtypes. *Journal of Pathology*, **2014**, 232, 32-42	9.4	39
65	Primary cutaneous anaplastic large cell lymphoma shows a distinct miRNA expression profile and reveals differences from tumor-stage mycosis fungoides. *Experimental Dermatology*, **2012**, 21, 632-4	4	39
64	microRNA expression in erythropoiesis and erythroid disorders. *British Journal of Haematology*, **2010**, 150, 144-51	4.5	36
63	Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks. *Molecular Immunology*, **2005**, 42, 31-8	4.3	32
62	Aberrant expression of the neuronal transcription factor FOXP2 in neoplastic plasma cells. *British Journal of Haematology*, **2010**, 149, 221-30	4.5	31
61	The Circulating Transcriptome as a Source of Biomarkers for Melanoma. *Cancers*, **2019**, 11,	6.6	28
60	Bortezomib action in multiple myeloma: microRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?. *Blood Cancer Journal*, **2012**, 2, e83	7	27

59	Stratification and therapeutic potential of PML in metastatic breast cancer. *Nature Communications*, **2016**, 7, 12595	17.4	26
58	Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. *British Journal of Haematology*, **2009**, 146, 396-407	4.5	25
57	Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients. *PLoS ONE*, **2017**, 12, e0181711	3.7	25
56	Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. *Leukemia*, **2014**, 28, 362-72	10.7	24
55	MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas. *British Journal of Haematology*, **2007**, 138, 479-86	4.5	24
54	Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. *Pathology Research and Practice*, **2018**, 214, 1110-1114	3.4	20
53	IgG responses to salivary gland extract of Ixodes ricinus ticks vary inversely with resistance in naturally exposed sheep. *Medical and Veterinary Entomology*, **2002**, 16, 186-92	2.4	20
52	Transcriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple Myeloma. *PLoS ONE*, **2013**, 8, e66121	3.7	20
51	MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential. *Current Genomics*, **2015**, 16, 349-58	2.6	18
50	Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining. *Histopathology*, **2012**, 61, 18-25	7.3	18
49	MicroRNAs as Biomarkers of B-cell Lymphoma. *Biomarker Insights*, **2018**, 13, 1177271918806840	3.5	18
48	Sensitivity Limit of Nanoparticle Biosensors in the Discrimination of Single Nucleotide Polymorphism. *ACS Sensors*, **2016**, 1, 1110-1116	9.2	17
47	Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms. *Journal of Molecular Diagnostics*, **2018**, 20, 34-45	5.1	16
46	miRNAs in B-cell lymphoma: Molecular mechanisms and biomarker potential. *Cancer Letters*, **2017**, 405, 79-89	9.9	16
45	Therapeutic strategies targeting glioblastoma stem cells. *Recent Patents on Anti-Cancer Drug Discovery*, **2013**, 8, 216-27	2.6	14
44	Nanoparticle-Based Discrimination of Single-Nucleotide Polymorphism in Long DNA Sequences. *Bioconjugate Chemistry*, **2017**, 28, 903-906	6.3	13
43	Aberrant expression of microRNA biosynthetic pathway components is a common feature of haematological malignancy. *British Journal of Haematology*, **2009**, 145, 545-8	4.5	13
42	Antigenic profile of Ixodes ricinus: effect of developmental stage, feeding time and the response of different host species. *Parasite Immunology*, **2001**, 23, 549-56	2.2	13

41	DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. *Pathology*, **2017**, 49, 731-739	1.6	12
40	Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP. *Experimental and Molecular Pathology*, **2015**, 99, 537-45	4.4	12
39	Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens. *PLoS ONE*, **2011**, 6, e23916	3.7	10
38	Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma. *Annals of Diagnostic Pathology*, **2018**, 34, 89-93	2.2	9
37	MicroRNA expression in chronic lymphocytic leukaemia. *British Journal of Haematology*, **2009**, 147, 398-402	4.5	9
36	Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC). *F1000Research*, **2016**, 5, 2020	3.6	9
35	The Urinary Transcriptome as a Source of Biomarkers for Prostate Cancer. *Cancers*, **2020**, 12,	6.6	8
34	Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study. *International Journal of Cancer*, **2020**, 147, 1315-1324	7.5	8
33	CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma. *Haematologica*, **2011**, 96, 78-86	6.6	8
32	MicroRNAs and Metastasis. *Cancers*, **2019**, 12,	6.6	8
31	High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma. *Annals of Diagnostic Pathology*, **2018**, 34, 27-30	2.2	7
30	Pre-targeting with ultra-small nanoparticles: boron carbon dots as drug candidates for boron neutron capture therapy. *Journal of Materials Chemistry B*, **2021**, 9, 410-420	7.3	7
29	Conjugated Polymers As Molecular Gates for Light-Controlled Release of Gold Nanoparticles. *ACS Applied Materials & Interfaces*, **2015**, 7, 15692-5	9.5	5
28	The Role of Chemically Modified DNA in Discrimination of Single-Point Mutation through Plasmon-Based Colorimetric Assays. *ACS Applied Nano Materials*, **2018**, 1, 3741-3746	5.6	5
27	Expression profiling of persistent polyclonal B-cell lymphocytosis suggests constitutive expression of the AP-1 transcription complex and downregulation of Fas-apoptotic and TGFbeta signalling pathways. *Leukemia*, **2009**, 23, 581-3	10.7	5
26	Therapeutic Pretargeting with Gold Nanoparticles as Drug Candidates for Boron Neutron Capture Therapy. *Particle and Particle Systems Characterization*, **2020**, 37, 2000200	3.1	5
25	Multi-site tumor sampling (MSTS) improves the performance of histological detection of intratumor heterogeneity in clear cell renal cell carcinoma (CCRCC). *F1000Research*,5, 2020	3.6	4
24	Circular RNAs and cancer: Opportunities and challenges. *Advances in Clinical Chemistry*, **2020**, 99, 87-146	5.8	4

23	Blocking probe as a potential tool for detection of single nucleotide DNA mutations: design and performance. *Nanoscale*, **2017**, 9, 16205-16213	7.7	3
22	MicroRNAs as Oncogenes and Tumor Suppressors **2013**, 223-243		3
21	MicroRNAs in Metastasis and the Tumour Microenvironment. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
20	Heparin length in the coating of extremely small iron oxide nanoparticles regulates theranostic applications. *Nanoscale*, **2021**, 13, 842-861	7.7	3
19	An Integrative Omics Approach Reveals Involvement of in Hepatic Metastatic Progression of Colorectal Cancer. *Cancers*, **2020**, 12,	6.6	2
18	Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC). *Cancers*, **2021**, 13,	6.6	2
17	MicroRNAs as B-cell lymphoma biomarkers. *Blood and Lymphatic Cancer: Targets and Therapy*, **2015**, 25	2.6	1
16	MicroRNAs: A Brief Introduction **2013**, 1-24		1
15	Circulating MicroRNAs as Non-Invasive Biomarkers **2013**, 567-588		1
14	MicroRNAs in Platelet Production and Activation **2013**, 101-116		1
13	Comparison of Choi and HansTalgorithms by immunohistochemistry and quantitative reverse transcriptase-PCR - letter. *Clinical Cancer Research*, **2010**, 16, 3805-6	12.9	1
12	Radiological outcomes following manual and robotic-assisted unicompartmental knee arthroplasty. *Bone & Joint Open*, **2021**, 2, 191-197	2.8	1
11	Written in Blood: Kissing Disease miRNAs Could Predict Outcome of Patients With Chronic Lymphocytic Leukaemia. *EBioMedicine*, **2015**, 2, 489-90	8.8	
10	Circulating MicroRNAs as Cellular Messengers **2013**, 589-605		
9	The MicroRNA Decalogue of Cancer Involvement **2013**, 199-221		
8	Regulation of Hypoxia Responses by MicroRNA Expression **2013**, 267-285		
7	MicroRNA Expression in Avian Herpesviruses **2013**, 137-151		
6	MicroRNA in B-Cell Non-Hodgkin's Lymphoma: Diagnostic Markers and Therapeutic Targets **2013**, 403-418		

List of Publications

5 MicroRNA Expression in Cutaneous T-Cell Lymphomas **2013**, 449-461

4 Release of MicroRNA-Containing Vesicles Can Stimulate Angiogenesis and Metastasis in Renal Carcinoma **2013**, 607-622

3 MicroRNAs in Diffuse Large B-Cell Lymphoma **2013**, 419-433

2 MicroRNAs and Blood Cancers **2014**, 129-153

1 MicroRNA involvement in invasion and metastasis **2022**, 47-62